Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2017
Pharmacy Choice - News - Generic Drugs - January 20, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 51     Next >>     Go To Page:

1/20/17 - Advanced Drug Delivery Technology, Route Of Administration, End User Market Analysis & Trends 2016-2025: Increasing Demand for Generic Drugs and Biosimilars
Research and Markets has announced the addition of the "Advanced Drug Delivery Market Analysis& Trends- Technology, Route Of Administration, End User- Forecast to 2025" report to their offering. The Global Advanced Drug Delivery Market is poised to grow at a CAGR of around 7.8% over the next decade to reach approximately $330.70 billion by 2025..
1/20/17 - Biosimilars Create Opportunities for Sustainable Cancer Care
"Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale and significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world," said ESMO President Professor Fortunato Ciardiello. In Europe, price reductions for biosimilars are expected to range from 20-40%:.
1/20/17 - Custopharm Acquires Two ANDA Pharmaceutical Products From Perrigo
By a News Reporter-Staff News Editor at Drug Week HYPERLINK " http://www.custopharm.com/"\ nCustopharm, Inc., a U.S. leader in generic injectable products, announced that it has acquired two paragraph IV abbreviated new drug application products from HYPERLINK " http://www.perrigo.com/"\ nPerrigo Company plc. William Larkins, chief executive offi
1/20/17 - Global Biosimilar Monoclonal Antibodies Market: Trend Analysis & Forecast to 2022
Dublin- Research and Markets has announced the addition of the "Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022" report to their offering. Europe is the largest biosimilar monoclonal antibodies market globally. Due to favorable regulatory policies designed by the European Medical Association and since Europe was
1/20/17 - Global Biosimilar Monoclonal Antibodies Market: Trend Analysis & Forecast to 2022 - Research and Markets
Research and Markets has announced the addition of the "Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022" report to their offering. Due to favorable regulatory policies designed by the European Medical Association and since Europe was the first region to draft guidelines for approval of biosimilar products, the Eu
1/20/17 - Lannett Announces Approval For Lopinavir And Ritonavir Oral Solution USP, 80 Mg/20 Mg Per mL
By a News Reporter-Staff News Editor at Drug Week- Lannett Company, Inc. announced that it received approval last week from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg per mL, the therapeutic equivalent to the reference listed drug, Kaletra Oral Soluti
1/20/17 - New Healthcare Economics Data Have Been Reported by Investigators at Department of Economics (Reference pricing with endogenous generic entry)
According to news originating from Bergen, Norway, by NewsRx correspondents, research stated, "Reference pricing intends to reduce pharmaceutical expenditures by increasing demand elasticity and stimulating generic competition. For more information on this research see: Reference pricing with endogenous generic entry. Journal of Health Economics, 2
1/20/17 - Researchers from Department of Biomedical Sciences Report New Studies and Findings in the Area of Antirheumatics (Biosimilars in IBD: from theory to...
Our news editors obtained a quote from the research from the Department of Biomedical Sciences, "Importantly for patients with IBD, CT-P13 was the first biosimilar to infliximab that obtained regulatory approval by the European Medicines Agency in September 2013 and by the FDA in April 2016. In May 2016, SB2 was the second biosimilar to infliximab
1/20/17 - The Knowledge Group Has Scheduled a Live Webcast on Resolving Patent Dispute Under BPCIA
Aside from the updates and recent developments, they will further discuss 2017 strategies which will be helpful for both innovators and biosimilar applicants. Key issues that will be covered in this course are: Supreme Court to hear the Amgen-Sandoz Fight Case Background The Neupogen // Zarxio? Biosimilar Dispute Questions the Supreme Court wil
1/19/17 - Biologics and Biosimilars Market Trends, Top Manufactures, Market Demands, Industry Growth Analysis & Forecast: 2022
Biologics and Biosimilars Market report biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine. Biosimilars are officially approved versions of original innovator products, and can be manufactured when the original product's patent expires.Pune, Maharashtra-
1/19/17 - Biosimilars Create Opportunities for Sustainable Cancer Care
LUGANO, Switzerland, January 19, 2017/ PRNewswire/. "Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale and significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world," said ESMO President Professor Fortunato Ciardiello. In Europe, price reducti
1/19/17 - Hikma receives approval for Sodium Oxybate Oral Solution
Release date- 18012017- London- Hikma Pharmaceuticals PLC,, the fast growing multinational pharmaceutical group, announces that its wholly owned US subsidiary, Roxane Laboratories, Inc., has received an approval from the US Food and Drug Administration for its Sodium Oxybate Oral Solution, 500 mg/mL, the generic equivalent to Xyrem. Roxane is curre
1/19/17 - Hikma Receives FDA Approval for Sodium Oxybate Generic for Narcolepsy with Cataplexy
Multinational London-based pharmaceutical group Hikma Pharmaceuticals PLC's wholly owned US subsidiary Roxane Laboratories Inc has received an approval from the US Food and Drug Administration (FDA) for its Sodium Oxybate Oral Solution, 500 mg/mL, the generic equivalent to Xyrem by Jazz Pharmaceuticals.
1/18/17 - ACR Statement on FDA Biosimilar Interchangeability Draft Guidance
"The ACR is pleased to see the FDA issue draft guidance on biosimilar interchangeability," expressed Dr. While the ACR is still reviewing the document and will provide detailed comments to the FDA in the coming weeks, our initial reaction is that the draft guidance strikes a good balance between ensuring safety and efficacy while also getting biosi
1/18/17 - Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review
Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira *, has been accepted for regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration. "The acceptance of our regulatory filings by the FDA and EMA is a critical milestone as we explore innovative ways for biosimil
1/18/17 - CADILA SETTLES PATENT DISPUTE
Nissan Chemical Industries Limited, and Kowa Pharmaceuticals America Inc. Zydus Cadila, the parent company of Cadila Healthcare, has received the license to market its generic version of Livalo from 2 May 2023 or earlier under certain circumstances.
1/18/17 - Considerations in Demonstrating Interchangeability With a Reference Product; Draft Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "Considerations in Demonstrating Interchangeability With a Reference Product." This guidance is one in a series of guidances that FDA has developed to implement the Biologics Price Competition and Innovation Act of 2009.
1/18/17 - Determination That SYMMETREL (Amantadine Hydrochloride), Syrup, 50 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or...
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to SYMMETREL, and it will allow FDA to continue to approve ANDAs that reference SYMMETREL if all other legal and regulatory requirements are met. The 1984 amendments include what is now section 505 of the Federal Food, Dr
1/18/17 - Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin [Tehran Times (Iran)]
-Elite Pharmaceuticals, Inc. today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016. Following our recent announcement regarding a successful FDA meeting for our immediate release Oxycodone HCl product SequestOx, I am now very pleased to announce these positive topline study results for an...
1/18/17 - FDA's Approach to Generic Drug Development: Director of the Division of Therapeutic Performance to Deliver Keynote Address
FDA will provide a keynote address at the 14th annual Controlled Release Delivery conference when it returns to London on the 3rd 4th April.
1/18/17 - Findings in Inflammatory Bowel Disease Reported from J. Jahnsen and Co-Researchers [Clinical experience with infliximab biosimilar Remsima (CT-P13)...
Findings in Inflammatory Bowel Disease Reported from J. Jahnsen and Co-Researchers. By a News Reporter-Staff News Editor at Biotech Week Current study results on Digestive System Diseases and Conditions- Inflammatory Bowel Disease have been published. According to news originating from Lorenskog, Norway, by NewsRx editors, the research stated, "M
1/18/17 - Global Active Pharmaceutical Ingredients/API Market 2017-2021: Increasing Uptake of Biopharmaceuticals / Growing Importance of Generics / Increasing Incidence of Chronic Diseases [Tehran Times (Iran)]
-Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients/API Market by Type, Manufacturer, Synthesis, Product Drug, Therapy- Global Forecast to 2021" report to their offering. The Active Pharmaceutical Ingredients Market in Terms of Value is Expected to Reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 20
1/18/17 - Hikma Pharmaceuticals Gets US Approval For Generic Cataplexy Drug
LONDON- Drugmaker Hikma Pharmceuticals PLC on Wednesday said its Roxane Laboratories Inc subsidiary in the US has received approval for its sodium oxybate oral product. Xyrem's owner, Jazz Pharmaceuticals PLC, reported net sales of the drug of USD955.0 million in 2015.. Hikma shares were up 1.9% to 1,950.00 pence on the news.
1/18/17 - Hikma's Unit Roxane Gets US Approval For Generic Sodium Oxybate Oral Solution
LONDON- Hikma Pharmaceuticals Plc announced Wednesday that its unit Roxane Laboratories, Inc. has received an approval from the US Food and Drug Administration for its Sodium Oxybate Oral Solution, 500 mg/mL, the generic equivalent to Xyrem. Roxane is currently involved in patent litigation concerning this product in the US District Court for the D
1/18/17 - Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet; Creating an Expandable Proprietary Medicine Platform
This acquisition represents yet another important strategic move for the Group to realize its strategy of building a family of well-known and trusted household proprietary brands with a wide geographical presence in Asia spanning from Hong Kong, China to Malaysia and Indonesia, etc. With the successful completion of the acquisition of Ho Chai Kung
Articles(s): 1 - 25 of 51     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415